Compare JFBR & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JFBR | VRAX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Israel | United Kingdom |
| Employees | 11 | N/A |
| Industry | Other Specialty Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.7M |
| IPO Year | N/A | 2021 |
| Metric | JFBR | VRAX |
|---|---|---|
| Price | $3.01 | $0.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 91.8K | ★ 19.7M |
| Earning Date | 03-31-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.10 |
| 52 Week High | $7.87 | $1.18 |
| Indicator | JFBR | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 42.90 |
| Support Level | $0.47 | $0.10 |
| Resistance Level | $3.70 | $0.26 |
| Average True Range (ATR) | 0.34 | 0.03 |
| MACD | -0.26 | 0.00 |
| Stochastic Oscillator | 35.58 | 23.11 |
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.